COVID-19 mRNA vaccine

BIOLOGICAL6 trials

Sponsors

Stemirna Therapeutics, CanSino Biologics Inc., Vaccine Company, Inc., GlaxoSmithKline, CastleVax Inc.

Conditions

COVID-19COVID-19 PandemicRespiratory Syncytial Virus InfectionsSARS-CoVSARS-CoV-2

Phase 1

A Phase I/II Clinical Trial in Healthy People Aged 18 Years and Above

CompletedNCT05144139

Stemirna TherapeuticsCOVID-19 Pandemic

Start: 2021-12-03End: 2022-11-11Updated: 2022-12-28

Phase I Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

CompletedNCT05373485

CanSino Biologics Inc.COVID-19

Start: 2022-05-17End: 2022-08-08Updated: 2024-12-04

Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa

CompletedNCT05938075

Vaccine Company, Inc.SARS-CoV, SARS-CoV-2

Start: 2023-08-04End: 2024-07-25Updated: 2024-12-10

Phase 2

Phase II Clinical Trial of COVID-19 mRNA Vaccine in Adults Aged 18 Years and Older

CompletedNCT05373472

CanSino Biologics Inc.COVID-19

Start: 2022-07-06End: 2022-09-21Updated: 2024-12-04

Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

RecruitingNCT07215520

CastleVax Inc.COVID-19

Start: 2025-11-03End: 2026-08-19Target: 200Updated: 2025-11-06

Phase 3

A Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus (RSV) When Given Alone and Together With a COVID-19 mRNA Vaccine in Adults Aged 50 Years and Above

CompletedNCT06374394

GlaxoSmithKlineRespiratory Syncytial Virus Infections

Start: 2024-04-29End: 2025-03-31Updated: 2025-12-26

Related Papers

Safety, immunogenicity, persistence and dose evaluation of the CS-2034 mRNA COVID-19 vaccine: a phase II randomized controlled trial in healthy Chinese adults.

2025-11-20

Safety and immunogenicity of the COVID-19 mRNA vaccine CS-2034: A randomized, double-blind, dose-exploration, placebo-controlled multicenter Phase I clinical trial in healthy Chinese adults.

2023-10-282 citations